alexa A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
Pharmaceutical Sciences

Pharmaceutical Sciences

Advances in Pharmacoepidemiology and Drug Safety

Author(s): Fattovich G, Giustina G, Favarato S, Ruol A

Abstract Share this page

Abstract AIMS: The aim of this study was to assess the incidence of fatal, life-threatening side effects and the de novo appearance of non-hepatic morbidity during interferon alfa therapy for chronic viral hepatitis. The relationship of these adverse events to actual total dose and duration of interferon was also evaluated. METHODS: We conducted a retrospective study at 73 Italian centers of 11,241 consecutive patients with chronic viral hepatitis who underwent interferon alfa treatment. RESULTS: Five patients died during interferon therapy due to liver failure (n = 4) or complications arising from sepsis. Life-threatening side effects were observed in eight patients: two cases where depression developed and led to a suicide attempt and six patients with bone marrow suppression (granulocytes < 500/mm3 or platelets < 25,000/mm3). These symptoms and signs completely disappeared after interferon withdrawal. During interferon treatment, 131 patients developed the following de novo non-hepatic disorders: symptomatic thyroid disease (n = 71), impotence (n = 5), systemic autoimmune disease (n = 5), immune-mediated dermatologic disease (n = 14), diabetes mellitus (n = 10), cardiovascular disease (n = 7), psychosis n = 10), seizures (n = 4), peripheral neuropathy (n = 3) and hemolytic anemia (n = 2). Most of these complications are reversible or can be ameliorated. Fatal or life-threatening side effects were not related to actual total dose or duration of interferon alfa, while the majority of patients with de novo non-hepatic morbidity received medium/high doses (> 200 million units) of interferon alfa or were treated for periods longer than 16 weeks (68\% and 80\%, respectively). CONCLUSIONS: Treatment with interferon alfa may have fatal or life-threatening side effects, their incidence in this study being low (0.04\% and 0.07\%, respectively) and perhaps no different than in untreated patients with chronic viral hepatitis. Moreover de novo non-hepatic morbidity occurred in 1.2\% of patients, and the dose and duration of interferon therapy seem important in determining the frequency of this complication. The development of clinically-overt thyroid disease was most common.
This article was published in J Hepatol and referenced in Advances in Pharmacoepidemiology and Drug Safety

Relevant Expert PPTs

Relevant Speaker PPTs

  • Sundeep Kumar Upadhyaya
    PPT Version | PDF Version
  • Li Yu-Jung
    Intra-maxillary Drug delivery and Bio-sensing via Dental Implant and its considerations
    PPT Version | PDF Version
  • Muhamed Fakhri Omer
    Cathodoluminescence petrography for provenance studies of the sandstones of Ora Formation (Devonian-Carboniferous), Iraqi Kurdistan Region, Northern Iraq
    PPT Version | PDF Version
  • Mustafa M Hariri
    Importance of methods’ selection in the geosciences studies and exploration
    PPT Version | PDF Version
  • Afsar Rahbar
    Studies of the importance of Cytomegalovirus infection in breast cancer
    PPT Version | PDF Version
  • Carsten Worsoe
    The value of the “simulated study” as a tool to predict actual leachables in parenteral drug products
    PPT Version | PDF Version
  • Jim Polarine
    Case studies of human fl ora and spore contamination in clean rooms
    PPT Version | PDF Version
  • Diane Paskiet
    Qualifi cation of extractables & leachables from container closure systems in drug products- Introduction to the Product Quality Institute (PQRI) recommendations
    PPT Version | PDF Version
  • Gulay Yelken Demirel
    Challenges in parenteral formulation development studies and an evaluation from QbD point of view
    PPT Version | PDF Version
  • Li-Chun Tsou
    Drug delivery device strategy for patient centric therapies
    PDF Version
  • Neervalur V Raghavan
    Systematic approach to development of aqueous drug formulation and drug device combination injectable products and challenges
    PPT Version | PDF Version
  • Jianfeng Hong
    Extractable and leachable studies of parenteral infusion and transfusion products
    PPT Version | PDF Version
  • Panayiotis P Constantinides
    Parenteral Drug Nanodispersions : Manufacturing, Characterization and In Vitro/In Vivo Performance Evaluation
    PPT Version | PDF Version
  • Jan Voskuil
    How antibodies can prevent medical progress and how they can be great tools?
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version